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ABSTRACT: LDN-212320 (3) was found to be a potent
EAAT2 activator at a translational level, restoring the normal
clearance of glutamate and providing neuronal protection.
Since the pharmacologic activation of EAAT2 represents a
valuable strategy to relieve neuropathic pain, we synthesized
novel activators (4a−f) of EAAT2. Among them 4f, analyzed
in comparison with 3 by different paradigms in a rat model of
oxaliplatin-induced neuropathic pain, showed the better
antihypersensitive profile being able to fully counteract the
oxaliplatin-induced neuropathy.
■ INTRODUCTION
In mammals, the glutamate is the prevalent excitatory
neurotransmitter in the central nervous system (CNS).1 It is
necessary for regular brain activity including memory, learning,
and cognition. In order to avoid overstimulation of glutamate
receptors that can lead to neuronal damages or death, the
concentration of glutamate in the extracellular environment
must be lower than ∼1 μM, which represents the excitotoxic
level. Inappropriate regulation of glutamatergic neurotransmis-
sion and the consequent excitotoxicity lead to an array of
somatic, psychiatric, and neurological diseases, including
neuropathic pain.1
The tight coupling of excitatory neurotransmitter release
with rapid reuptake represents a pivotal element of the regular
sensory neurotransmission.
Interplay between the increase in primary afferent activity
and the impairment of glutamate reuptake at afferent synapses
was suggested as a possible mechanism of neuropathy.1 The
excitatory amino acid transporters (EAATs), a family of specific
high-affinity membrane transporters, mediate the recovery of
synaptic glutamate. Five EAATs (EAAT1−5) from mammals
have been discovered. EAAT1−3 correspond to rodents
GLAST, GLT-1, and EAAC1, respectively.2 In the CNS,
EAAT1 and EAAT2 are found principally on presynaptic
processes of astrocytes tightly linked to excitatory synaptic
interactions being able to keep low extracellular glutamate
concentrations. In particular, EAAT2 is accountable for up to
80−90% of the total extracellular glutamate uptake activity.2
The neuronal pathological changes observed during the
neuropathic pain suggested an impaired or altered function of
EAAT2 in the proximity of afferent synapses. The down-
regulation of EAAT2 in the dorsal horn of the spinal cord was
related to hyperalgesia induced by chronic nerve pain,
chemotherapy, and morphine tolerance. Furthermore, the
inhibition of the glial glutamate transporter in the dorsal
horn, elicited by drugs, hypersensitized animals to peripheral
stimulation.3
Due to the abundant distribution in the CNS, GLT-1/
EAAT2 represents novel potential targets for preventing
excessive glutamate accumulation.4
Although there is scarce information regarding the exact
mechanism that modulates GLT-1/EAAT2 or the other Na+-
dependent glutamate transporters, findings suggest that the
transcriptional and/or post-transcriptional events control the
expression of GLT-1/EAAT2.5
The upregulation of EAAT2 induced by ceftriaxone (1)6 or
gene transfer7 prevented the development of pathological pain
evoked by nerve injury.
Albeit β-lactams have been traditionally employed as
antimicrobial agents, a remarkable additional effect in the
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host was described by Rothstein et al.8 The results indicated β-
lactam antibiotics as effective enhancer of GLT-1 expression,
and among them 1 was identified as transcriptional activator of
EAAT2, being able to increase GLT-1/EAAT2 expression in a
concentration-dependent manner. Neuroprotective activity of 1
from glutamate toxicity was effective in in vitro models of
motor neuron deterioration and ischemic injury. Furthermore,
1 was found to alter EAAT2 gene expression, to enhance
glutamate transport in primary human fetal astrocytes, to delay
loss of neuronal cells, to increase muscle strength, and to
enhance mouse survival in an in vivo model of amyotrophic
lateral sclerosis (ALS).9 The activation of the expression of glial
GLT-1 led to an antinociceptive effect in diverse rodent pains
comprising neuropathic pain.10 It was reported that extra-
cellular levels of glutamate were considerably boosted after
repeated chemotherapeutic bortezomib administration to rats.
β-Lactam antibiotics (i.e., 1) can significantly and selectively
stimulate glutamate transporter expression and function,
enhancing glutamate uptake and modulating extracellular
glutamate homeostasis at the spinal level.11 It was found that
in rats co-treated with 1, bortezomib-induced hyperalgesic
effect could be precluded and SNCV (i.e., sensory nerve
conduction velocity, a well-known neuropathy marker) might
be kept at basal value showing that the neuropathy was
associated with glutamate homeostasis.12
Even if the possibility of a direct stimulation of EAAT2
activity has been suggested,13 these actions appear mediated by
means of an augmented transcription of the EAAT2 gene.14
Antibiotic 1 stimulated nuclear translocation of p65 and
initiation of the transcription nuclear factor κB (NF-κB).14
Activated NF-κB then binds to the NF-κB binding site of the
GLT-1/EAAT2 promoter region and upregulates the tran-
scription of this gene. So a decrease of glutamate concentration
in the synaptic space relieves the neurotoxic effects of excessive
glutamate.14
Unfortunately, the exact mechanism by which 1 increases
EAAT2 gene expression is still not clarified. Because EAAT2
can be upregulated by transcriptional or translational activation,
the continuous efforts to develop EAAT2 activators have
spurred the discovery of novel chemical entities.15 In this way,
Colton et al.16 by means of a high-throughput screening (HTS)
in search of compounds able to increase EAAT2 translation
succeeded in the development of 16 classes of structurally
unrelated molecules from which a pyridazine-based series (2a−
e) was further investigated by means of structure−activity
relationship (SAR) analysis for elevating EAAT2 protein
levels.17 It was demonstrated that the 2-pyridyl, the pyridazine,
and the benzyl thioether moieties were required for activity and
that compounds containing a methyl substituted benzyl group,
2,6-dichlorobenzyl ring, and 2-(2-Cl-6-F-phenylethyl) substitu-
ent on the sulfur linker significantly increased EAAT2 protein
levels.17
Thiopyridazine 2a caused a dose-dependent increase in
EAAT2 protein levels after a 24 h exposure. Modification of the
benzyl thioether resulted in several derivatives (2b−d) that
increased EAAT2 levels by >6-fold at <5 μM after 24 h.
Furthermore, 2a increased EAAT2 levels 3.5- to 3.9-fold after
24 h with an EC50 of 0.5 μM. In this series, 3 (3-[(2-
methylbenzyl)sulfenyl]-6-(pyridine-2-yl)pyridazine) subse-
quently reported as LDN/OSU-021232018 enhanced EAAT2
levels only 3.5- to 0.3-fold after 24 h, and successive studies by
Lin et al. demonstrated that in an in vivo study, 3 showed
strong potency along with satisfactory pharmacokinetic
parameters without relevant toxic profile at the tested doses.
Moreover, 3 was able to protect cultured neuronal cells from
glutamate-mediated excitotoxic injury and death via transla-
tional EAAT2 activation.18 Notably, 3 evidenced a lot of
additional effects that resulted in beneficial epilepsy and ALS
animal models proposing that this new approach is potentially
useful for treating both chronic and acute neurodegenerative
disorders.1
■ RESULTS AND DISCUSSION
On the basis of these findings, we expanded our main interest
in neuroprotective agents,19−21 focusing our attention on the
search for new EAAT2 activators based on the pyridazine
scaffold of 3. Presently, we describe the chemical synthesis and
the analysis of biological profile of hitherto unknown
compounds 4a−f (Chart 1) in which the benzyl moiety of 3
was replaced by more lipophilic aryl or heteroaryl substituents.
Briefly, as outlined in Scheme 1, 4a−f were prepared using
pyridyl-pyridazinone 5 as the starting material synthesized
according to a previously reported procedure.22 The trans-
formation of ketone 5 by means of Lawesson’s reagent in dry
DMF at reflux instead of P2S5 in pyridine at 120 °C
17 afforded
pyridazinthione 6 that was in turn alkylated by treatment with
the appropriate aryl- or heteroarylmethyl bromide to give the
expected thioethers 4a−f.
All six compounds were screened for pan assay interference
compounds (PAINS),23 and none of them were found to
contain structural features recognized as “frequent hitters” in
high throughput screens.
The pain relieving effects of the novel synthesized EAAT2
activators (4a−f) were preclinically evaluated in a model of
neuropathic pain induced by oxaliplatin in comparison to 3.17
The anticancer drug oxaliplatin is a cytotoxic agent belonging
to the diaminocyclohexane platinum family. The compound is
Chart 1. Reference and Title Compounds
Scheme 1a
aReagents and conditions: (i) Lawesson reagent, dry toluene, reflux, 4
h; (ii) K2CO3, dry DMF, BrCH2R, rt, from 1 to 20 h.
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currently used as first-line chemotherapy in metastatic color-
ectal cancer, and it represents a relevant option as adjuvant
therapy for neoplastic diseases of different tissues. A painful
neuropathy that persists between cycles is the limiting side
effect, tightly correlated with specific alterations of the nervous
system.24 The repeated administration of oxaliplatin (2.4 mg
kg−1 ip, daily) induced decrease of pain threshold starting from
day 7 of treatment. In the present study, the assessment of a
response to a noxious mechanical stimulus was attained by
means of the paw pressure test25 (Table 1).
In oxaliplatin + vehicle treated rats, the weight tolerated on
the posterior paw progressively decreased to 46.1 ± 0.5 g on
day 7 and to 44.7 ± 1.2 g on day 14 in comparison to the
control value of about 62 g (Table 1).
Compound 3 (3 mg kg−1 sc) was administered daily starting
from the first day of oxaliplatin treatment. Compounds 4a−f
were subcutaneously administered at doses equimolar to 3,
following the same experimental protocol. Compound 3 limited
the mechanical hypersensitivity induced by oxaliplatin treat-
ment and increased the weight tolerated on posterior paw by
67.1% on day 7 and 76.4% on day 14. Among the new
compounds, 4f (3.28 mg kg−1) showed the better anti-
hypersensitive profile. It was able to fully counteract the
oxaliplatin-induced neuropathy on day 14. Compound 4d (3.42
mg kg−1) displayed a higher antihypersensitivity effect in
comparison to 3, increasing the pain threshold by 86.2% on day
14. A lower efficacy was recorded on the same day with 3.43 mg
kg−1 of 4e (72.5%), while 4a (3.37 mg kg−1), 4b (3.37 mg
kg−1), and 4c (3.37 mg kg−1) counteracted the oxaliplatin-
induced mechanical hypersensitivity by 40.1%, 44.3%, and
31.7%, respectively (Table 1).
The pain threshold to thermal noxious stimulus was
evaluated by plantar test,26 applying a heat stimulation to the
posterior paw with a 30 s cutoff time (Table 2). Oxaliplatin
reduced the withdrawal latency from about 17 s (vehicle +
vehicle) to 9.0 ± 1.0 s on day 7 and 10.6 ± 0.5 s on day 14.
Compounds 3 and 4f fully counteracted thermal hyper-
sensitivity induced by oxaliplatin on day 14. Compounds 4a,
4d, and 4e were partially active while 4b and 4c were not
effective (Table 2).
Von Frey27 and cold plate test24 allowed evaluating the
sensitivity to stimuli which usually do not provoke pain (Tables
3 and 4, respectively). The withdrawal threshold to a non-
noxious mechanical stimulus diminished in oxaliplatin-treated
animals from 23.7 ± 0.6 g (vehicle + vehicle) to 12.4 ± 1.2 g
(oxaliplatin + vehicle) on day 7 and from 23.1 ± 0.4 g (vehicle
+ vehicle) to 11.6 ± 0.5 g (oxaliplatin + vehicle) on day 14
(Table 3). On day 14, repeated treatment with 3 mg kg−1 of 3
increased the withdrawal threshold by 75.9% while 3.28 mg
kg−1 of 4f fully prevented the pain threshold alteration, reaching
a value of 23.8 ± 1.0 g. Compounds 3 and 4f were partially
effective also at day 7 (withdrawal threshold increase of 51.3%
and 62.8%, respectively).
Treatment with 4b, 4d, and 4e partially counteracted the
neuropathic state on day 14, with an increase of the pain
threshold of 68.7%, 64.3%, and 67.8%, respectively. Com-
pounds 4a and 4c showed lower efficacy (53% and 33%,
respectively) (Table 3). The sensitivity to a cold non-noxious
stimulus is shown in Table 4 (cold plate test). The licking
latency decreased from about 19 s (vehicle + vehicle) to 14.3 ±
0.3 s on day 7 and 12.0 ± 1.2 s on day 14. Repeated
administration of 3 and 4f fully prevented the pain threshold
alteration on day 14 (22.5 ± 0.5 s and 22.0 ± 0.8 s,
respectively). Compound 4b reached a value of 18.0 ± 0.2 s
while 4a, 4d, and 4e partially counteracted the thermal
hypersensitivity induced by oxaliplatin (Table 4).
Table 1. Effect of Repeated Administration of Compounds 3
and 4a−f on Oxaliplatin Induced Hyperalgesia in the Rat
Paw Pressure Testa
weight (g)
day
treatment
dose, mg kg−1
sc
7 after
treatment
14 after
treatment
vehicle + vehicle 62.5 ± 0.5 61.4 ± 0.7
oxaliplatin + vehicle 46.1 ± 0.5*** 44.7 ± 1.2***
oxaliplatin + 3 3 57.1 ± 0.5∧∧∧ 57.5 ± 0.3∧∧∧
oxaliplatin + 4a 3.37 51.9 ± 1.0∧∧ 51.4 ± 0.7∧∧
oxaliplatin + 4b 3.37 51.3 ± 1.3∧∧ 52.1 ± 0.5∧∧
oxaliplatin + 4c 3.37 48.4 ± 1.2 50.0 ± 0.5∧
oxaliplatin + 4d 3.42 55.3 ± 0.9∧∧ 59.1 ± 1.0 ∧∧∧
oxaliplatin + 4e 3.43 54.7 ± 0.9∧∧ 56.8 ± 1.0∧∧
oxaliplatin + 4f 3.28 58.6 ± 0.6∧∧∧ 62.8 ± 1.3∧∧∧
aPain: mechanical noxious stimulus. Oxaliplatin (2.4 mg kg−1, ip) was
administered daily ip for 2 weeks dissolved in glucose solution (5%).
Compounds were dissolved in 1% DMSO/1% polyethylene glycol
400/0.2% Tween 80/10% hydroxypropyl-β-cyclodextrin/saline and
administered daily sc for 2 weeks, starting from the first day of
oxaliplatin administration. Control animals received vehicles. Paw
pressure test was used to measure the sensitivity to a mechanical
noxious stimulus on days 7 and 14. ***P < 0.001 vs vehicle + vehicle
treated animals; ∧P < 0.05, ∧∧P < 0.01, and ∧∧∧P < 0.001 vs oxaliplatin
+ vehicle treated rats. Each value represents the mean of 10 rats.
Table 2. Effect of Repeated Administration of Compounds 3
and 4a−f on Oxaliplatin Induced Thermal Hyperalgesia in
the Rat Plantar Testa
withdrawal latency (s)
day
treatment
dose, mg kg−1
sc
7 after
treatment
14 after
treatment
vehicle + vehicle 16.3 ± 1.0 17.8 ± 0.2
oxaliplatin + vehicle 9.0 ± 1.0** 10.6 ± 0.5***
oxaliplatin + 3 3 14.1 ± 0.5 18.3 ± 0.3∧∧∧
oxaliplatin + 4a 3.37 14.2 ± 0.3 15.5 ± 0.6∧∧
oxaliplatin + 4b 3.37 12.5 ± 1.5 13.8 ± 1.2
oxaliplatin + 4c 3.37 11.6 ± 0.8 13.7 ± 1.5
oxaliplatin + 4d 3.42 12.8 ± 1.4 15.1 ± 0.8∧∧
oxaliplatin + 4e 3.43 14.3 ± 2.1 15.8 ± 0.7∧∧
oxaliplatin + 4f 3.28 15.2 ± 0.6∧∧ 18.7 ± 1.3∧∧∧
aPain: thermal noxious stimulus. Oxaliplatin (2.4 mg kg−1, ip) was
dissolved in 5% glucose solution and administered daily ip for 2 weeks.
Compounds were dissolved in 1% DMSO/1% polyethylene glycol
400/0.2% Tween 80/10% hydroxypropyl-β-cyclodextrin/saline and
administered daily sc for 2 weeks, starting from the first day of
oxaliplatin administration. Control animals received vehicles. Plantar
test was used to measure the sensitivity to a thermal noxious stimulus
on days 7 and 14. **P < 0.01 and ***P < 0.001 vs vehicle + vehicle
treated animals; ∧∧P < 0.01 and ∧∧∧P < 0.001 vs oxaliplatin + vehicle
treated rats. Each value represents the mean of 10 rats.
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■ CONCLUSIONS
The imbalance concerning the release and reuptake of
glutamate may cause disturbances in the neuronal signaling,
leading to neurological and psychiatric disorders, including
neuropathic pain. The high-affinity membrane excitatory amino
acid transporter EAAT2 mediates the recovery of glutamate
from the synaptic space. When EAAT2 function is impaired or
altered in the proximity of afferent synapses, neuronal and glial
pathological changes occur, evoking painful hypersensitivity.
Considering EAAT2 a potential target, a small series of EAAT2
activators 4a−f was developed and tested in animal model of
neuropathic pain induced by oxaliplatin. Using 3 as the
reference compound, we assessed the response to different
noxious and non-noxious mechanical and thermal stimuli after
repeated administration of the anticancer drug (2.4 mg kg−1 ip,
daily). Among the novel compounds, 4f (3.28 mg kg−1) showed
the best antihypersensitive profile being able to fully counteract
the oxaliplatin-induced neuropathy on day 14. These data
suggested that the introduction of an appropriate and more
lipophilic heteroarylmethyl thioether in the pyridyl-pyridazine
scaffold of 3 results in an increase in the pain threshold.
In this way, 4f is a candidate to deep preclinical studies aimed
to characterize its potentiality against pain. The pharmacody-
namic profile of the molecule deserves investigations about the
possible modulation of EAAT2. Both the enhancement of
glutamate transporter function and expression should be
considered.
■ EXPERIMENTAL SECTION
General Methods. All chemicals used were of reagent grade.
Yields refer to purified products and are not optimized. Melting points
were determined in open capillaries on a Gallenkamp apparatus and
are uncorrected. Merck silica gel 60 (230−400 mesh) was used for
column chromatography. Merck TLC plates, silica gel 60 F254 were
used for TLC. NMR spectra were recorded by means of Bruker AC
200 and Bruker DRX 400 AVANCE spectrometers in the indicated
solvents (TMS as internal standard); the values of the chemical shifts
are expressed in ppm and the coupling constants (J) in Hz. Mass
spectra were recorded on a ThermoFinnigan LCQ-Deca or an Agilent
1100 LC/MSD instrument. High resolution mass spectra (HMRS)
were recorded on LTQ Orbitrap (ThermoFisher). The purity of
compounds 4a−f was assessed by RP-HPLC and was found to be
higher than 95%. An Agilent 1100 series system equipped with a
Zorbax Eclipse XDB-C8 (4.6 mm × 150 mm, 5 μm) column was used
in the HPLC analysis with acetonitrile−methanol−water (50:30:20) as
the mobile phase at a flow rate of 1.0 mL/min. UV detection was
achieved at 254 nm.
General Procedure for the Synthesis of Pyridyl-pyridazine
Thioethers (4a−f). Compounds 4a−f were synthesized by reaction
of 6 (0.53 mmol) with the suitable bromomethyl derivative (0.80
mmol) in dry DMF (5.0 mL) using K2CO3 as the base. The resulting
mixture was stirred at room temperature for the suitable time (from 90
min to 20 h). At the end of reaction the inorganic material was filtered
off and washed with EtOAc. The resulting organic filtrate was washed
with water (3 × 10 mL), dried over anhydrous Na2SO4, and
concentrated in vacuo. The crude was purified by flash chromatog-
raphy on silica gel, eluting with petroleum ether/EtOAc (from 8:2 to
6:4 v/v) to give the expected compounds as solids.
4-((6-(Pyridin-2-yl)pyridazin-3-ylthio)methyl)benzo[c][1,2,5]-
oxadiazole (4f). Compound 4f was obtained after 3 h of reaction
time (yield 99%) as a yellow solid (mp 177.4−178.2 °C). 1H NMR
(CDCl3, 400 MHz) δ 5.04 (s, 2H), 7.29−7.37 (m, 2H),7.43 (d, J =
8.8, 1H), 7.60 (d, J = 7.2, 1H), 7.70 (d, J = 8.8, 1H), 7.85 (t, J = 7.8,
1H), 8.34 (d, J = 8.8, 1H), 8.57 (d, J = 8.0, 1H), 8.67 (d, J = 4.8, 1H).
13C NMR (CDCl3, 100 MHz): 29.8, 115.3, 121.1, 124.1, 124.6, 126.7,
126.9, 130.5, 131.6, 137.1, 149.0, 149.4, 153.2, 156.1, 160.8. MS (ESI):
m/z 321.8 (M + H+). An analytical sample was obtained by
recrystallization from ethyl acetate. HRMS (ESI): m/z calculated for
[C16H11N5OS + H
+] requires 322.0757, found 322.0760.
Table 3. Effect of Repeated Administration of Compounds 3
and 4a−f on Oxaliplatin-Induced Allodynia in the Rat Von
Frey Testa
withdrawal latency (s)
day
treatment
dose, mg kg−1
sc
7 after
treatment
14 after
treatment
vehicle + vehicle 23.7 ± 0.6 23.1 ± 0.4
oxaliplatin + vehicle 12.4 ± 1.2*** 11.6 ± 0.5***
oxaliplatin + 3 3 18.2 ± 0.3∧ 20.6 ± 0.6∧∧∧
oxaliplatin + 4a 3.37 17.6 ± 0.7∧ 17.7 ± 0.4∧∧
oxaliplatin + 4b 3.37 17.6 ± 0.7∧ 19.5 ± 0.5∧∧∧
oxaliplatin + 4c 3.37 13.5 ± 1.0 15.4 ± 0.7∧
oxaliplatin + 4d 3.42 18.8 ± 0.5∧∧ 19.0 ± 0.6∧∧∧
oxaliplatin + 4e 3.43 16.4 ± 0.4∧ 19.4 ± 0.8∧∧
oxaliplatin + 4f 3.28 19.5 ± 0.6∧∧∧ 23.8 ± 1.0∧∧∧
aPain: mechanical non-noxious stimulus. Oxaliplatin (2.4 mg kg−1, ip)
was administered daily ip for 2 weeks dissolved in glucose solution
(5%). Compounds were dissolved in 1% DMSO/1% polyethylene
glycol 400/0.2% Tween 80/10% hydroxypropyl-β-cyclodextrin/saline
and administered daily sc for 2 weeks, starting from the first day of
oxaliplatin administration. Control animals were treated with vehicles.
Von Frey test was used to measure the sensitivity to a mechanical non-
noxious stimulus on days 7 and 14. ***P < 0.001 vs vehicle + vehicle
treated animals; ∧P < 0.05, ∧∧P < 0.01, and ∧∧∧P < 0.001 vs oxaliplatin
+ vehicle treated rats. Each value represents the mean of 10 rats.
Table 4. Effect of Repeated Administration of Compounds 3
and 4a−f on Oxaliplatin Induced Allodynia in the Rat Cold
Plate Testa
withdrawal latency (s)
day
treatment
dose, mg kg−1
sc
7 after
treatment
14 after
treatment
vehicle + vehicle 19.0 ± 0.6 18.3 ± 0.9
oxaliplatin + vehicle 14.3 ± 0.3** 12.0 ± 1.2***
oxaliplatin + 3 3 17.0 ± 0.2∧ 22.5 ± 0.5∧∧∧
oxaliplatin + 4a 3.37 16.0 ± 0.6 16.5 ± 0.4
oxaliplatin + 4b 3.37 18.0 ± 1.0∧ 18.0 ± 0.2∧∧
oxaliplatin + 4c 3.37 14.5 ± 1.2 15.6 ± 0.3
oxaliplatin + 4d 3.42 17.8 ± 0.6∧ 17.5 ± 0.4∧∧
oxaliplatin + 4e 3.43 15.8 ± 0.4 16.3 ± 1.3
oxaliplatin + 4f 3.28 19.4 ± 1.3∧∧ 22.0 ± 0.8∧∧∧
aPain: thermal non-noxious stimulus. Oxaliplatin (2.4 mg kg−1, ip) was
administered daily ip for 2 weeks dissolved in glucose solution (5%).
Compounds were dissolved in 1% DMSO/1% polyethylene glycol
400/0.2% Tween 80/10% hydroxypropyl-β-cyclodextrin/saline and
administered daily sc for 2 weeks, starting from the first day of
oxaliplatin administration. Control animals were treated with vehicles.
Cold plate test was used to measure the sensitivity to a thermal non-
noxious stimulus on days 7 and 14. **P < 0.01 and ***P < 0.001 vs
vehicle + vehicle treated animals; ∧P < 0.05, ∧∧ P < 0.01 and ∧∧∧P <
0.001 vs oxaliplatin + vehicle treated rats. Each value represents the
mean of 10 rats.
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